Pulmonary Medicine

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jeffrey B. Velotta, MD, FACS Guest: Anne Gonzalez, MD, M.Sc. For patients with non-small cell lung cancer, staging accuracy is critical in guiding treatment decisions that can significantly affect outcomes. In this expert-led discussion, Dr. Gerard Silvestri sits down with Drs. Anne Gonzalez and Jeffrey Velotta break down what clinicians need to know, including how to perform thorough EBUS staging, why PET scans alone aren’t enough, and what the updated TNM classification means for surgical planning. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Gonzalez is a pulmonary and critical care physician, a researcher in the Translational Research and Respiratory Diseases Program, and an Associate Professor in the Department of Medicine at McGill University in Montreal; and Dr. Velotta is a leading thoracic surgeon specializing in complex cancers, a Clinical Professor in the Department of Clinical Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, and a Clinical Assistant Professor in the Department of Surgery at UCSF School of Medicine in California. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses. However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages. References: Pathogens J ImmunolVaccines (Basel)J Clin Invest USA-CRP-24-0038 July 2025

Guest: Martha Kingman, DNP, FNP-C Guest: Ioana Preston, MD Guest: Jean M. Elwing, MD Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are living with PAH require careful evaluation, those with comorbidities and/or psychosocial challenges can require additional consideration when developing a treatment plan that improves outcomes.

Guest: Vallerie V. McLaughlin, MD Guest: Ioana Preston, MD Guest: Kelly Chin, MD, MSCA Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our experts’ insights can help you elevate your practice and develop effective PAH treatment plans.

Guest: Jorge Nivea, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile. Joining Dr. Jacob Sands to talk more about these findings and their implications are Drs. Elaine Shum and Estelamari Rodriguez. Dr. Shum is an Assistant Professor in the Department of Medicine at NYU Grossman School of Medicine, and Dr. Rodriguez is an Associate Director of Community Outreach, Thoracic Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Health System.

Guest: Jessica Shull, PhD Guest: Joshua Solomon, MD Host: Ryan Quigley Patients with pulmonary fibrosis often face anxiety and emotional distress that go unadressed during their care. Given this unmet need, a digital cognitive behavioral therapy (CBT) platform was designed to support emotional wellbeing alonside medical treatment. Mr. Ryan Quigley sits down with Drs. Jessica Shull and Joshua Solomon, who presented at the 2025 American Thoracic Society International Conference to explore how this platform may enhance quality of life, support therapy adherence, and integrate into routine care. Dr. Shull is the Director of Digital Health and a Clinical Science Liaison at Vicore Pharma, and Dr. Solomon is a Professor of Medicine in Pulmonary Care and the Director of the Interstitial Lung Disease Program at National Jewish Health.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Guest: Divya Shankar, MD A recent study investigated whether pulse-dose corticosteroids offer a benefit over lower doses in managing acute exacerbations of idiopathic pulmonary fibrosis (IPF). Join Dr. Divya Shankar as she explains the real-world data, variability in prescribing patterns, and outcomes observed in different levels of care. Divya Shankar is an Assistant Professor of Medicine at Boston University Chobanian and Avedisian School of Medicine as well as a Pulmonary and Critical Care Physician at Boston Medical Center, and she spoke about this topic at the 2025 American Thoracic Society International Conference.

Guest: Daniel Paul Vena, PhD A recent study explored whether lateral wall collapse can predict hypoglossal nerve stimulation efficacy in patients with obstructive sleep apnea (OSA). Join Dr. Daniel Vena as he explains the findings from this research and areas for future explanation. Dr. Vena is an Assistant Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, and he spoke about this topic at the 2025 American Thoracic Society International Conference.

Guest: Isabel Bazan, MD, BA As race-neutral reference equations have become the standard in pulmonary function tests (PFTs), a recent study explored the potential impact of this change on diagnosis and treatment of severe asthma. Join Dr. Isabel Bazan as she dives into the data and explains its implications for patient categorization and access to care. Dr. Bazan is an Assistant Professor of Medicine at Yale School of Medicine, and she spoke about this topic at the 2025 American Thoracic Society International Conference.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient’s respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Guest: Fernando López-Ríos, MD, PhD Guest: Christian Rolfo, MD, PhD Guest: Prof. Charlie Gourley In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testing and the evolving role of IHC in lung and ovarian cancers. Topics of conversation include the following: Watch the on-demand video to gain expert insights on optimising IHC HER2 testing and interpreting results in lung and ovarian cancer. The full programme is also featured on the COR2ED website, here: HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kaitlin Batley, MD Guest: Esra Caylan, MD Thymidine kinase 2 deficiency (TK2d) presents with a variability of symptoms, including respiratory, neurological, and ocular ones, making it difficult to diagnose. Because of this, a multidisciplinary care team that’s tailored to each patient’s needs is key to effectively identifying and treating this disease. Hear about the role of a multidisciplinary team and strategies for personalizing treatment with Drs. Kaitlin Batley and Esra Caylan. Dr. Batley is the Director of Pediatric Neuromuscular Medicine at Children’s Health and an Assistant Professor at UT Southwestern Medical Center. Dr. Caylan is a pediatric pulmonologist at Children’s Health and an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center.

Host: Nathan Falk, MD, MBA, FAAFP Guest: Ashwin Basavaraj, MD Early recognition and diagnosis of non-tuberculosis mycobacteria (NTM) and bronchiectasis are key for optimal patient management. However, these conditions are often misdiagnosed as COPD or asthma, leading to significant challenges and delays in treatment. Join Drs. Nate Falk and Ashwin Basavaraj as they share perspectives on accurately diagnosing NTM and bronchiectasis with early symptom recognition, a thorough patient history, and testing. Dr. Falk is a board-certified family medicine physician, a Professor and Founding Residency Director for Family Medicine at Florida State University in partnership with BayCare Health System, and the Assistant Dean for Graduate Medical Education at Florida State University. Dr. Basavaraj is an Associate Professor of Medicine at New York University Grossman School of Medicine, the Director of the Bronchiectasis and NTM Education Program at NYU Langone Health, and the Section Chief of Pulmonary, Critical Care, and Sleep Medicine at Bellevue Hospital Center. This program is produced in partnership with the American College of CHEST Physicians and is sponsored by Insmed Incorporated.

Guest: Nasser Altorki, MD Nasser Altorki, MD, chief of thoracic surgery at NewYork-Presbyterian and Weill Cornell Medicine, shares the results of a first-of-its-kind study evaluating low-dose radiation combined with immunotherapy for neoadjuvant treatment of non-small cell lung cancer (NSCLC) tumors. The dual-therapy treatment of durvalumab in combination with stereotactic body radiation was almost twice as effective at tumor killing compared to durvalumab alone. © 2025 NewYork-Presbyterian

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization, and patients often continue to have severe symptoms despite therapy.​ Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients. In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 LaryngoscopeAllergyJ Allergy Clin Immunol Pract ©2024 Amgen and AstraZeneca. All rights reserved. US-96000 Last Updated 12/24

Guest: Clete A. Kushida, MD, PhD Guest: Sally Ibrahim, MD, FAAP Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.